1 / 1

Global Market Trends in Alzheimer’s Disease Therapies: Opportunities and Challenges

The Alzheimer’s disease therapy market is experiencing shifts due to patent expirations and the influx of generics, leading to decreased global spending despite increased treatment volumes driven by demographic changes. Aricept (Donepezil) remains the leading product globally but faces competition from generics. Sales distribution highlights North America (38%) as the largest market, followed by Europe (30%), while regions with younger populations like Latin America (4%) lag behind. The sector sees significant R&D investment, with a notable decline in spending on branded therapies first reported in 2011.

toril
Télécharger la présentation

Global Market Trends in Alzheimer’s Disease Therapies: Opportunities and Challenges

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global market facts and trends regarding Alzheimer‘s disease therapies: • Patent losses and entrance of generics in the market lead to lower global spending in this therapy area; however volume increases asa consequence of demographic change • Aricept (Donepezil) is still the leading product worldwide, however exposed to generic competition • According to regions/countries the distribution of sales shows: North America on the top (38%, one-year-period from April 2011 upto march 2012), followed by Europe (30%), Africa, Asia, Australasia (28%) and Latin America (4%). This distribution also reflects the age structures, because Latin America has a quite young population, compared internationally • The Alzheimer‘s disease area is characterized by an intensive R&D with many products under development Spending on predominantly brand-dominated Alzheimer’s disease therapies declined for the first time in 2011 Alzheimer’s Therapies Global Spending and Volume, 2001-2011 VOLUME (STANDARD UNITS BN) SALES (US$BN) Source: IMS MIDAS®, Dec 2011 Four brands have been losing exclusivity in key countries since 2010, opening this therapy space to generic competition Alzheimer’s Therapy Sales Exposed to Generic Competition (2010-2015) US Spain Japan Europe Canada Europe US US PRE-EXPIRY SALES* (US$BN) Europe Canada Source: IMS MIDAS®, March 2012 * Molecule sales in year prior to loss of exclusivity. INFOGRAFIK 09_2/2012

More Related